Journal of Clinical Psychopharmacology最新文献

{"title":"Oculogyric Crisis and Torticollis Temporally Associated With Short-Term Coadministration of Fluoxetine and Hydroxyzine in a Child With Attention-Deficit/Hyperactivity Disorder.","authors":"Mustafa Çobaner, Ali Evren Tufan","doi":"10.1097/JCP.0000000000002237","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002237","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics Associated With Nightmares During Lemborexant Treatment in Psychiatric Patients: A Retrospective Study.","authors":"Kazuya Yasuda, Hiroaki Kubo, Shunsuke Tamura, Ryuichiro Takeda, Ryuji Ikeda, Yoji Hirano","doi":"10.1097/JCP.0000000000002194","DOIUrl":"10.1097/JCP.0000000000002194","url":null,"abstract":"<p><strong>Background: </strong>A dual orexin receptor antagonist, lemborexant (LEM) is widely prescribed for the treatment of insomnia, especially among patients with psychiatric disorders. However, LEM-induced nightmares may exacerbate existing psychiatric symptoms and lead to the discontinuation of treatment. Despite its still growing clinical application, few studies have identified risk factors associated with LEM-induced nightmares. The aim of this study was to elucidate the clinical factors associated with LEM-induced nightmares in clinical settings.</p><p><strong>Procedures: </strong>This retrospective study included 327 psychiatric patients who were prescribed LEM at the University of Miyazaki Hospital between January 2020 and September 2024. Risk factors were identified by comparing demographic and clinical characteristics between patients who experienced nightmares (nightmare group) and those who did not (non-nightmare group).</p><p><strong>Results: </strong>The incidence of nightmares (8.0%) exceeded the incidence reported in previous clinical trials. Multivariate logistic regression revealed that younger age (10 to 29 years), concomitant use of tandospirone, and switching from benzodiazepine drugs were significantly associated with an increased risk of nightmares. Receiver Operating Characteristic curve analysis indicated an age cutoff of ≤49 years for increased risk. Cox regression analysis further demonstrated that these factors were associated with earlier onset of nightmares following LEM initiation.</p><p><strong>Conclusions: </strong>This study revealed that patients aged 50 years or older who were prescribed LEM experienced a lower incidence of nightmares than younger patients. When prescribing LEM-particularly in younger patients, in combination with tandospirone, or following benzodiazepines discontinuation-clinicians should consider potential nightmares associated with LEM. These findings offer clinically meaningful insights for optimizing insomnia treatment while minimizing LEM-associated risks.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147982063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withania somnifera (Ashwagandha) as an Adjunctive Treatment to Antipsychotic Medications for Patients With Schizophrenia.","authors":"Stephen R Marder, Deanna L Kelly, Gerard DeVera, Jennifer Osing Zaranski, Fiona Whelan, Catherine A Sugar, Robert W Buchanan","doi":"10.1097/JCP.0000000000002229","DOIUrl":"10.1097/JCP.0000000000002229","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of Withania somnifera extract (WSE), or Ashwagandha, on symptoms of schizophrenia and to investigate decreases in proinflammatory markers as a possible mechanism of action.</p><p><strong>Methods: </strong>Schizophrenia subjects with a history of a recent exacerbation were randomly assigned to receive double-blind adjunctive treatment either with WSE or placebo for 12 weeks. Outcomes were assessed using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression Scale (CGI), and the Perceived Stress Scale (PSS). Inflammatory markers were measured at baseline and 12 weeks.</p><p><strong>Results: </strong>Among 47 randomized subjects, 24 received WSE and 23 received placebo. WSE treatment was not associated with a greater reduction in symptoms on the PANSS, the CGI, or the PSS. We did not find a significant effect of WSE on inflammatory markers and we did not find an association between changes in inflammatory measures and changes in symptoms.</p><p><strong>Conclusion: </strong>This clinical trial failed to find that WSE resulted in a statistically significant improvement of clinical measures or inflammatory markers. Disruptions from the COVID pandemic, the small sample size, heterogeneity, and baseline differences in psychopathology between the groups were important limitations of the study. However, the pattern that we observed did not indicate that the findings would have been different with a larger sample size or that the findings were influenced by the baseline differences.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Variants Associated With Treatment Response in Bipolar Disorder: A Systematic Review.","authors":"Ana Luiza da Silva Selani, Beatriz Cristina Betarelli, Marília Aparecida Batista Dos Santos, Ana Elisa Palha Guerra, Marcela Forgerini","doi":"10.1097/JCP.0000000000002205","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002205","url":null,"abstract":"<p><strong>Purpose: </strong>To identify genetic variants associated with pharmacological treatment response in individuals with bipolar disorder (BD).</p><p><strong>Methods: </strong>A systematic review was conducted by searching PubMed, Scopus, PsycINFO, SciELO, and LILACS from inception through January 2025. Eligible studies examined associations between genetic variants and pharmacological treatment response in BD. Study selection, eligibility assessment, and methodological quality assessment were independently performed by 2 reviewers. Extracted data included publication year, study design, setting, eligibility criteria, sample size, participant characteristics, genetic variants, treatment type, response definition, clinical outcomes, and main findings.</p><p><strong>Findings: </strong>Of 3372 records screened, 69 studies, reported in 100 publications, met inclusion criteria. These studies included 31,760 participants, of whom 8897 were women. Most publications used a cohort design (n=46) and were conducted in Europe (n=53). The most frequently investigated genes included BDNF (n=17), GSK3β (n=15), SLC6A4 (n=14), COMT (n=7), CREB1 (n=7), DRD2 (n=7), and 5-HT2A (n=7). Mood stabilizers were the most commonly used treatments, followed by antidepressants and total sleep deprivation interventions. Definitions of treatment response and outcome assessment methods varied considerably among studies. Consistent associations with treatment response were observed primarily for BDNF, especially the Val66Met variant (rs6265). Findings for GSK3β, SLC6A4, COMT, CREB1, DRD2, and 5-HT2A were heterogeneous . At least one methodological limitation was reported in 72 publications.</p><p><strong>Implications: </strong>Genetic variants appears to influence pharmacological treatment response in BD. Current evidence suggests more consistent associations for a limited subset of candidate genes. Findings for other variants remain inconsistent because of methodological heterogeneity across studies.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148412127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delusional Pseudotranssexualism Associated With Exogenous Estrogen in Schizoaffective Disorder: A Case Report.","authors":"Yi-Chih Shiao, Wan-Ting Chen, Yi-Wei Yeh, Shin-Chang Kuo, Sister Arlene Te, Yi-Guang Wang, Szu-Hao An, Chun-Yen Chen","doi":"10.1097/JCP.0000000000002193","DOIUrl":"10.1097/JCP.0000000000002193","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"503-504"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148015695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Escitalopram-Associated Myopericarditis in a Young Adult: A Case Report.","authors":"Ayşe Köksal","doi":"10.1097/JCP.0000000000002185","DOIUrl":"10.1097/JCP.0000000000002185","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"501-503"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clozapine-associated Retrograde Ejaculation: A Case Series With Positive Rechallenge.","authors":"Syed Ali Bokhari, Sarah Morcos, Raghad Naji, Louai Jalal, Daliya Maallah, Amr Abdel Aty","doi":"10.1097/JCP.0000000000002178","DOIUrl":"10.1097/JCP.0000000000002178","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"498-501"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Article Selected to Receive the Mitchell B. Balter Award for Publications in 2025.","authors":"","doi":"10.1097/JCP.0000000000002214","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002214","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"46 4","pages":"372"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148368591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Steatosis, Hepatic Fibrosis, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Schizophrenia Patients: An Exploratory Study From India.","authors":"Sandeep Grover, Nidhi Yadav, Harsh Sutail, Subho Chakrabarti, Ajay Duseja","doi":"10.1097/JCP.0000000000002159","DOIUrl":"10.1097/JCP.0000000000002159","url":null,"abstract":"<p><strong>Background: </strong>Although there is a large amount of data on the prevalence of metabolic syndrome, there are limited data on the prevalence of hepatic steatosis, hepatic fibrosis, and metabolic dysfunction-associated steatotic liver disease (MASLD) in schizophrenia patients. The present study aimed to evaluate the prevalence of MASLD, hepatic steatosis, hepatic fibrosis, and metabolic syndrome in a group of patients with schizophrenia.</p><p><strong>Methods: </strong>This cross-sectional study included 80 patients with schizophrenia spectrum disorder, with 40 patients receiving clozapine and 40 receiving other second-generation antipsychotics. Hepatic steatosis and fibrosis were quantified noninvasively using transient elastography (Fibroscan) to measure the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), respectively. The participants were also evaluated for anthropometry and metabolic abnormalities.</p><p><strong>Results: </strong>In the whole study sample, the prevalence was 37.5%, 33.75%, 33.75%, and 28.75% for metabolic syndrome, hepatic steatosis, MAFLD, and hepatic fibrosis, respectively. Compared with other antipsychotics, patients receiving clozapine had a higher prevalence of hepatic fibrosis and MAFLD.</p><p><strong>Conclusion: </strong>The present study suggests that about one-third of the schizophrenia patients on antipsychotics have hepatic steatosis and MAFLD and slightly more than one-fourth have hepatic fibrosis. These findings underscore the critical need for hepatic monitoring, including steatosis assessment, in patients receiving high-metabolic-risk antipsychotics.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"412-419"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risperidone-Associated Nocturnal Enuresis in an Adolescent.","authors":"Rahime Kaya, Nihal Yurteri","doi":"10.1097/JCP.0000000000002173","DOIUrl":"10.1097/JCP.0000000000002173","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"504-506"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147529347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}